Novo Holdings’ $16.5B bid for Catalent; Novartis’ $2.9B bolt-on; Endpoints Slack interview with John Evans; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

In a week where the com­pa­ny be­hind a top obe­si­ty drug an­nounced it will buy one of the biggest con­tract man­u­fac­tur­ers of those drugs, oth­er news could pale in com­par­i­son. But there’s plen­ty of oth­er big sto­ries on deals, earn­ings, sen­ate hear­ings, peo­ple and more — see if you missed any.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.